Cardiometabolic Medicine
The need for consistent updates and agile content is imperative for today’s clinician to remain current on the continuum of scientific data. In no therapeutic area is this more essential than in “Cardiometabolic Medicine,” a new term meant to encompass the interconnected and debilitating diagnoses of diabetes mellitus, heart failure, coronary artery disease/acute coronary syndrome, progressive renal insufficiency, and related disorders such as hypertension, hyperlipidemia, and hyperkalemia. These areas are subject to frequent pivotal trial publications, guidelines updates, FDA action, and outcomes assessments.
Our Tweetorials
Your new source for free CE/CME via Twitter!
Each program provides 0.5hr – 1.0hr credit for physicians, pharmacists, and nurses.
Determination of the Risk of Stroke in Patients with Atrial Fibrillation and Cancer: Current and Emerging Paradigm
1b) With the burgeoning #AFib population worldwide, effective #SPAF is hindered by #adherence issues, #underprescribing, & #underdosing....
Clinical Trial Data Review and Clinical Applications for Class III Antiarrhythmic Therapeutics for Patients with Atrial Fibrillation
2) .@SeguraCardio is discussing "Clinical Trial Data Review & Clinical Applications for Class III #Antiarrhythmic Therapeutics for Pts with...
What Every Cardiologist Should Know About ATTR-CM
2) Follow this 🧵to earn 0.5hr CE/#CME. This program is intended for #healthcare providers. Statement of accreditation & faculty disclosures at...
LATE-BREAKING DATA FROM AHA23: AZALEA-TIMI 71 SUPPORTS THE FACTOR XI HYPOTHESIS IN ATRIAL FIBRILLATION
2) Yes, #ChristianRuffMD just left the podium and we have MUCH to discuss in this LIVE program from #AHA23. Our guest author is Sid Patel MD...
Improving Outcomes and Symptom Burden in Patients with Atrial Fibrillation and Rapid Ventricular Response: New Data from AHA23
1b) That #EHRA affiliation is 🔑to today's program, as we focus on #AFib with rapid ventricular response #RVR. Atrial fibrillation with RVR leads...
Update from AHA23: New Data on Optimizing Lipid-Lowering Management in Statin-Intolerant and Statin-Resistant Patients
2) This program is supported by an educational grant from Esperion Therapeutics & is intended for #HCPs. Statement of accreditation &...
COUNTDOWN TO AHA AND NEW DATA ON THE SAFETY OF FXI INHIBITION IN AFIB
2) Actually, the #DOACs ARE safer than #VKAs, but there is still room for improvement in risk of both major & #gastrointestinal #Bleeding #GIB 🩸...
JOURNAL CLUB: Delphi Panel on Management of Life-Threatening DOAC-Associated GI Bleed
2a) 2⃣ very cool aspects of this work: first, it's truly #multidisciplinary, with international authors from #emergencymedicine,...
What Every Non-Cardiologist Should Know About ATTR-CM: A Primer
2) Our expert author is Ronald Witteles MD @Ron_Witteles, @StanfordMed IM program director, Professor of Medicine, #Cardiologist, Specialist in...
Early Rhythm Control to Improve Outcomes in Patients with Atrial Fibrillation
2) This program is intended for #healthcare providers & is supported by an independent educational grant from Sanofi. Statement of accreditation...
@Cardiomet_CE on Twitter
Your only source for ACCREDITED SoMe-delivered
serialized professional cardiometabolic education. Physicians, nurses, pharmacists–come one, come all!
On Twitter at @cardiomet_ce, we present a series of tweetorials, Twitter-delivered case studies, and Twitter Journal Clubs, each accredited for 0.5hr – 1.0hr CE/CME. Programs are presented by expert faculty in engaging and fully interactive format. Our unique program harnesses the reach, up-to-the-minute currency, and accessibility of social media to deliver a constant flow of accredited, interactive, expert-delivered educational programs to a multidisciplinary and interprofessional audience of engaged clinicians.